Evidence map›Paper›PMID 34949997›Full record

ArticleCase reports in oncology

Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour.

Charlotte Brinch, Marie Dehnfeld, Estrid Hogdall, Tim Svenstrup Poulsen, Anders Toxvaerd, Gina Al-Farra, Magnus Bergenfeldt, Anders Krarup-Hansen

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Charlotte BrinchDepartment of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Marie DehnfeldDepartment of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Estrid HogdallDepartment of Pathology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Tim Svenstrup PoulsenDepartment of Pathology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Anders ToxvaerdDepartment of Pathology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Gina Al-FarraDepartment of Radiology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Magnus BergenfeldtDepartment of Surgery, Skaane University Hospital, Lund, Sweden.
Anders Krarup-HansenDepartment of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Gentofte Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal stromal tumour (GIST) is the most common sarcoma and can be seen in any part of the gastrointestinal tract. The effect of tyrosine kinase inhibitors varies with mutation status in receptor tyrosine kinase KIT and in platelet-derived growth factor receptor A (

Indexed as

Gastrointestinal stromal tumourMultidisciplinary approachPDGFRA mutationSorafenib

Identifiers

PMID34949997
PMCPMC8647052
OpenAlexW3211720698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.